Related Experiment Video
Updated: Sep 11, 2026

Microsurgical Clip Obliteration of Middle Cerebral Aneurysm Using Intraoperative Flow Assessment
Published on: September 25, 2009
MitraClip®: Two Weeks after Implantation
Juliëtte F Velu1, Hans H de Boer2, Berto J Bouma1
1Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands.
Abstract:
A 73-year-old male received a percutaneous mitral valve repair with a MitraClip to treat severe (grade IV) symptomatic mitral regurgitation (MR). The MitraClip® procedure reduced the MR to grade I, but the patient died 14 days post-procedurally due to a pneumosepsis. Histological analysis of the MitraClip mesh covering showed a chronic inflammatory reaction with an abundance of multinucleated giant cells. Remarkably, signs of early onset clip-coverage were found, indicated by the presence of a few scattered myofibroblasts.
Insights
A patient with severe mitral regurgitation (MR) underwent successful MitraClip repair, reducing MR significantly. However, the patient later died from pneumosepsis, with histology revealing inflammation and early tissue coverage on the device.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Biomaterials Science
Background:
- Severe symptomatic mitral regurgitation (MR) poses significant clinical challenges.
- Percutaneous mitral valve repair using the MitraClip device offers a less invasive treatment option for MR.
- Understanding the long-term tissue response to implanted devices is crucial for patient outcomes.
Observation:
- A 73-year-old male patient with severe MR underwent successful MitraClip repair, reducing MR from grade IV to grade I.
- The patient experienced a fatal outcome (pneumosepsis) 14 days post-procedure.
- Histological examination of the MitraClip mesh revealed a chronic inflammatory reaction with multinucleated giant cells.
Findings:
- The MitraClip device demonstrated effectiveness in reducing mitral regurgitation.
- Histology showed a significant foreign body reaction, characterized by multinucleated giant cells.
- Early signs of tissue coverage (myofibroblast presence) on the MitraClip mesh were observed.
Implications:
- While MitraClip effectively treats MR, potential inflammatory responses and early tissue coverage warrant further investigation.
- The findings highlight the importance of monitoring for complications such as infection post-procedure.
- Further research is needed to understand the long-term biological interactions between the MitraClip device and cardiac tissue.
Related Concept Videos
Clot Retraction and Fibrinolysis
Ovarian Cycle
In Vitro Fertilization
The IVF process begins with ovarian stimulation, during which reproductive endocrinologists prescribe hormonal medications to stimulate the ovaries to produce multiple eggs instead of the single...

